d[Cha4]-AVP
![Cat.No. 3126 - d[Cha4]-AVP | Mpr-Tyr-Phe-Cha-Asn-Cys-Pro-Arg-Gly-NH2 | CAS No. 500170-27-4](http://resources.tocris.com/images/datasheets/structures/dcha4-avp_3126.png "Cat.No. 3126 - d[Cha4]-AVP | Mpr-Tyr-Phe-Cha-Asn-Cys-Pro-Arg-Gly-NH2 | CAS No. 500170-27-4")
Biological Activity
Potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.
Technical Data
| M. Wt | 1094.31 |
| Formula | C50H71N13O11S2 |
| Sequence |
XYFXNCPRG (Modifications: X-1 = Mpr, X-4 = Cha, Gly-9 = C-terminal amide, Disulfide bridge between X-1 - Cys-6) |
| Storage | Store at -20°C |
| CAS Number | 500170-27-4 |
| PubChem ID | 44419028 |
| InChI Key | ZKYCVZNKBXGNEK-ZTYVOHGWSA-N |
| Smiles | NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CC(N)=O)C(=O)N1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data
| Solubility | Soluble to 1 mg/ml in water |
Product Datasheets
References
References are publications that support the biological activity of the product.
Derick et al (2002) [1-Deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology 143 4655 PMID: 12446593
Cheng et al (2004) Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J.Med.Chem. 47 2375 PMID: 15084136
Pena et al (2007) Design and synthesis of the frist selective agonists for the rat vasopressin V1b receptor: based on modifications of deamino-[cys1]arginine vasopressin at positions 4 and 8. J.Med.Chem. 50 835 PMID: 17300166
If you know of a relevant reference for d[Cha4]-AVP, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: d[Cha4]-AVP, d[Cha4]-AVP supplier, Potent, selective, human, V1b, agonists, V2, Receptors, Vasopressin, 3126, Tocris Bioscience
1 Citation for d[Cha4]-AVP
Citations are publications that use Tocris products. Selected citations for d[Cha4]-AVP include:
Perígolo-Vicente et al (2014) IL-6, A1 and A2aR: a crosstalk that modulates BDNF and induces neuroprotection. Biochem Biophys Res Commun 449 477 PMID: 24845382
Do you know of a great paper that uses d[Cha4]-AVP from Tocris? Please let us know.
Reviews for d[Cha4]-AVP
There are currently no reviews for this product. Be the first to review d[Cha4]-AVP and earn rewards!
Have you used d[Cha4]-AVP?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Secretin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Peptide Hormone Receptors Product Listing
A collection of over 200 products for peptide hormone receptors, the listing includes research tools for the study of:
- Anterior Pituitary Regulation
- Blood Pressure Regulation
- Feeding and Appetite Regulation
- Glucose Regulation
- Peptide Hormone Processing
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
